Endra Life Sciences announces results from Taeus Liver device feasibility study

Endra Life Sciences (NDRA) announced new results from its 2025 Taeus Liver device feasibility study demonstrating that Taeus’ thermo-acoustic fat fraction measurement closely tracks the MRI-PDFF standard at critical liver fat fraction thresholds of 12%-17% and 20%-22%. The company said, “These thresholds separate mild, moderate and severe disease, are widely used to make clinical therapy decisions in routine practice and are important for enrolling patients in clinical trials. The high accuracy of TAEUS at these specific points strengthens its potential as a practical, low-cost tool for the booming MASLD/MASH and obesity drug development landscape. In the recently completed feasibility study of 40 subjects with BMI ranging from 21 to 47, ENDRA evaluated the performance of its TAFF biomarker test against MRI-PDFF at decision thresholds that segment patients from mild to moderate-to-severe steatosis.”